Nkarta, Inc. NKTX

NKTX Company Overview

Nkarta, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for the treatment of cancer and autoimmune diseases. The company operates within the broader biotechnology and cell therapy industries, with a strategic emphasis on allogeneic, “off-the-shelf” immunotherapies designed to overcome manufacturing and scalability limitations commonly associated with autologous cell therapies. Nkarta’s core development programs have centered on chimeric antigen receptor-natural killer (CAR-NK) therapies targeting hematologic malignancies and immune-mediated disorders.

The company’s primary value drivers are its proprietary NK-cell engineering platform, clinical-stage therapeutic candidates, and manufacturing capabilities supporting cryopreserved allogeneic cell products. Nkarta has positioned itself as a developer of scalable NK-cell therapies that may offer advantages in manufacturing consistency, outpatient administration potential, and broader patient accessibility compared with patient-specific CAR-T approaches. Founded in 2015, the company evolved from an early-stage immunotherapy platform developer into a publicly traded biotechnology company focused on advancing engineered NK-cell programs through clinical development.